Hoth Therapeutics (HOTH) shares advanced nearly 24% in recent Tuesday trading after the company said preliminary results of a preclinical study suggested that its HT-KIT drug inhibits and stabilizes tumor growth.
The study was undertaken through a sponsored scientific research agreement with NC State University, the company said.
Hoth said initial findings showed minimal changes in tumor volumes in treated animals, suggesting that the drug inhibited tumor growth. Tumor sizes were also consistent across the treated animals, indicating the drug's potential reproducibility and reliability, the company added.
Price: 1.09, Change: +0.21, Percent Change: +23.86
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。